Join the Liletta group to help and get support from people like you.
Liletta News
Asthma Attacks Increase for Some Women Taking Progestogen-Only Pill
THURSDAY, May 8, 2025 – Use of a combined oral contraceptive (COC) is not associated with asthma in women of reproductive age, but use of a progestogen-only pill (POP) is associated with an...
Big Post-Election Surge Seen in Online Sales of Morning-After Pills
WEDNESDAY, Nov. 13, 2024 – In the wake of Donald Trump's victory in the presidential election, retailers report that online sales of emergency contraceptives have soared. The spike in purchases of...
Breast Cancer Risk Elevated With Levonorgestrel-Releasing Intrauterine System Use
FRIDAY, Oct. 18, 2024 – Women using levonorgestrel-releasing intrauterine systems (LNG-IUS) have an increased risk for breast cancer, according to a study published online Oct. 16 in the Journal of...
FDA Approves Medicines360’s Supplemental New Drug Application for Liletta (levonorgestrel-releasing intrauterine system) 52 mg as Treatment of Heavy Menstrual Bleeding
SAN FRANCISCO, CA – July 10, 2023 – Medicines360, a global nonprofit organization with a mission to catalyze equitable access to quality medicines for women, announced today that the U.S. Food and...
FDA Approves Medicines360’s Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years
SAN FRANCISCO – Nov. 14, 2022 – Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, announced today that the U.S. Food and Drug Administration ...
FDA Medwatch Alert: Voluntary Recall of Certain Family Dollar Over-the-Counter Products
July 21, 2022 – Family Dollar is initiating a voluntary retail level product recall of certain products regulated by the U.S. Food and Drug Administration (FDA) that were stored and inadvertently...
FDA Approves Liletta (levonorgestrel-releasing intrauterine system) to Prevent Pregnancy for up to Six Years
SAN FRANCISCO and DUBLIN October 28, 2019 – Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, and Allergan plc (NYSE: AGN), a leading global p...
FDA Approves Liletta (levonorgestrel-releasing intrauterine system) to Prevent Pregnancy for up to Five Years
DUBLIN and SAN FRANCISCO October 16, 2018 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mis...
FDA Approves Liletta (levonorgestrel-releasing intrauterine system) to Prevent Pregnancy for up to Four Years
August 6, 2017 – Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to...